Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunoglobulin signature predicts risk of post-acute COVID-19 syndrome.
Cervia C, Zurbuchen Y, Taeschler P, Ballouz T, Menges D, Hasler S, Adamo S, Raeber ME, Bächli E, Rudiger A, Stüssi-Helbling M, Huber LC, Nilsson J, Held U, Puhan MA, Boyman O. Cervia C, et al. Among authors: stussi helbling m. Nat Commun. 2022 Jan 25;13(1):446. doi: 10.1038/s41467-021-27797-1. Nat Commun. 2022. PMID: 35078982 Free PMC article.
Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19.
Cervia C, Nilsson J, Zurbuchen Y, Valaperti A, Schreiner J, Wolfensberger A, Raeber ME, Adamo S, Weigang S, Emmenegger M, Hasler S, Bosshard PP, De Cecco E, Bächli E, Rudiger A, Stüssi-Helbling M, Huber LC, Zinkernagel AS, Schaer DJ, Aguzzi A, Kochs G, Held U, Probst-Müller E, Rampini SK, Boyman O. Cervia C, et al. J Allergy Clin Immunol. 2021 Feb;147(2):545-557.e9. doi: 10.1016/j.jaci.2020.10.040. Epub 2020 Nov 20. J Allergy Clin Immunol. 2021. PMID: 33221383 Free PMC article.
A distinct innate immune signature marks progression from mild to severe COVID-19.
Chevrier S, Zurbuchen Y, Cervia C, Adamo S, Raeber ME, de Souza N, Sivapatham S, Jacobs A, Bachli E, Rudiger A, Stüssi-Helbling M, Huber LC, Schaer DJ, Nilsson J, Boyman O, Bodenmiller B. Chevrier S, et al. Among authors: stussi helbling m. Cell Rep Med. 2020 Dec 26;2(1):100166. doi: 10.1016/j.xcrm.2020.100166. eCollection 2021 Jan 19. Cell Rep Med. 2020. PMID: 33521697 Free PMC article.
Profound dysregulation of T cell homeostasis and function in patients with severe COVID-19.
Adamo S, Chevrier S, Cervia C, Zurbuchen Y, Raeber ME, Yang L, Sivapatham S, Jacobs A, Baechli E, Rudiger A, Stüssi-Helbling M, Huber LC, Schaer DJ, Bodenmiller B, Boyman O, Nilsson J. Adamo S, et al. Among authors: stussi helbling m. Allergy. 2021 Sep;76(9):2866-2881. doi: 10.1111/all.14866. Epub 2021 Jun 30. Allergy. 2021. PMID: 33884644 Free PMC article.
Autoantibodies in COVID-19 correlate with antiviral humoral responses and distinct immune signatures.
Taeschler P, Cervia C, Zurbuchen Y, Hasler S, Pou C, Tan Z, Adamo S, Raeber ME, Bächli E, Rudiger A, Stüssi-Helbling M, Huber LC, Brodin P, Nilsson J, Probst-Müller E, Boyman O. Taeschler P, et al. Among authors: stussi helbling m. Allergy. 2022 Aug;77(8):2415-2430. doi: 10.1111/all.15302. Epub 2022 Apr 8. Allergy. 2022. PMID: 35364615 Free PMC article.
T-cell recovery and evidence of persistent immune activation 12 months after severe COVID-19.
Taeschler P, Adamo S, Deng Y, Cervia C, Zurbuchen Y, Chevrier S, Raeber ME, Hasler S, Bächli E, Rudiger A, Stüssi-Helbling M, Huber LC, Bodenmiller B, Boyman O, Nilsson J. Taeschler P, et al. Among authors: stussi helbling m. Allergy. 2022 Aug;77(8):2468-2481. doi: 10.1111/all.15372. Epub 2022 Jun 2. Allergy. 2022. PMID: 35567391 Free PMC article.
The Reply.
Stüssi-Helbling M, Arrigo M, Huber LC. Stüssi-Helbling M, et al. Am J Med. 2020 Feb;133(2):e64. doi: 10.1016/j.amjmed.2019.09.004. Am J Med. 2020. PMID: 31954478 No abstract available.
Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19).
Urwyler P, Charitos P, Moser S, Heijnen IAFM, Trendelenburg M, Thoma R, Sumer J, Camacho-Ortiz A, Bacci MR, Huber LC, Stüssi-Helbling M, Albrich WC, Sendi P, Osthoff M. Urwyler P, et al. Trials. 2021 Jan 4;22(1):1. doi: 10.1186/s13063-020-04976-x. Trials. 2021. PMID: 33397449 Free PMC article.
14 results